Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by JDavenporton Sep 30, 2022 10:12pm
159 Views
Post# 34998937

RE:RE:Prothena and Management's Reporting

RE:RE:Prothena and Management's Reporting
Agree, Sniper007, except that Bioasis does not mention any partners or licensees on its website, at all. The only references are contained in other media such as videos, presentations and in filings.
 
This allows Bioasis to avoid being specific about anything.
 
There needs to be a push to get Bioasis to 'fess up about all of its dealings. There is a possibility that Bioasis has no agreements whatsoever under which work is being conducted. I'm not saying this is so but I am saying that Bioasis's obfuscations suggest the possibility that Bioasis is dead in the water.
 
It's time for Bioasis to come clean.
 
This is not an attack on Bioasis. The share price tells us that investors consider Bioasis to be worth 15¢. Bioasis needs to tell shareholders and investors whether it's worth 15¢ or whether it's worth more or less than that.
 
In my opinion, Bioasis is getting dangerously close to being a company that regulators might want to investigate.
 
jd
<< Previous
Bullboard Posts
Next >>